Background In an attempt to explore cynomolgus monkeys as an animal model for Alzheimer's disease, the present study focused on the Alzheimer's biomarkers beta amyloid 142 (A42) in serum, and total tau (t-tau) and phosphorylated tau (p-tau) levels in cerebrospinal fluid. Methods We measured biomarker levels in Young and Aged cynomolgus monkeys and correlated these with performance on three delayed response tasks. Results The A42 concentration of the Aged monkeys was significantly lower than in the Young subjects, while the t-tau and p-tau did not significantly differ between the groups. The Young subjects performed significantly better than the Aged individuals on the memory tests. Only A42 levels were significantly correlated with performa...
International audienceAlzheimer's disease (AD) is the most common age-related neurodegenerative diso...
Introduction: Many publications consider that the Alzheimer's disease (AD) is exclusive to the human...
To diagnose and treat early-stage (preclinical) Alzheimer's disease (AD) patients, we need body-flui...
Background In an attempt to explore cynomolgus monkeys as an animal model for Alzheimer's disease, t...
Background: Due to their similarities in behavior and disease pathology to humans, non-human primate...
Pituitary adenylate cyclase activating polypeptide (PACAP) is associated with Alzheimer's disease (A...
Background:The Caribbean vervet monkey (Chlorocebus aethiops sabaeus) is a potentially valuable anim...
Pituitary adenylate cyclase activating polypeptide (PACAP) is associated with Alzheimer's disease (A...
Background:The Caribbean vervet monkey (Chlorocebus aethiops sabaeus) is a potentially valuable anim...
Abstract Monkeys are becoming important translational models of neurodegenerative disease. To facili...
International audienceAlzheimer's disease (AD) is the most common age-related neurodegenerative diso...
International audienceAlzheimer's disease (AD) is the most common age-related neurodegenerative diso...
International audienceAlzheimer's disease (AD) is the most common age-related neurodegenerative diso...
International audienceAlzheimer's disease (AD) is the most common age-related neurodegenerative diso...
International audienceAlzheimer's disease (AD) is the most common age-related neurodegenerative diso...
International audienceAlzheimer's disease (AD) is the most common age-related neurodegenerative diso...
Introduction: Many publications consider that the Alzheimer's disease (AD) is exclusive to the human...
To diagnose and treat early-stage (preclinical) Alzheimer's disease (AD) patients, we need body-flui...
Background In an attempt to explore cynomolgus monkeys as an animal model for Alzheimer's disease, t...
Background: Due to their similarities in behavior and disease pathology to humans, non-human primate...
Pituitary adenylate cyclase activating polypeptide (PACAP) is associated with Alzheimer's disease (A...
Background:The Caribbean vervet monkey (Chlorocebus aethiops sabaeus) is a potentially valuable anim...
Pituitary adenylate cyclase activating polypeptide (PACAP) is associated with Alzheimer's disease (A...
Background:The Caribbean vervet monkey (Chlorocebus aethiops sabaeus) is a potentially valuable anim...
Abstract Monkeys are becoming important translational models of neurodegenerative disease. To facili...
International audienceAlzheimer's disease (AD) is the most common age-related neurodegenerative diso...
International audienceAlzheimer's disease (AD) is the most common age-related neurodegenerative diso...
International audienceAlzheimer's disease (AD) is the most common age-related neurodegenerative diso...
International audienceAlzheimer's disease (AD) is the most common age-related neurodegenerative diso...
International audienceAlzheimer's disease (AD) is the most common age-related neurodegenerative diso...
International audienceAlzheimer's disease (AD) is the most common age-related neurodegenerative diso...
Introduction: Many publications consider that the Alzheimer's disease (AD) is exclusive to the human...
To diagnose and treat early-stage (preclinical) Alzheimer's disease (AD) patients, we need body-flui...